164 related articles for article (PubMed ID: 29122824)
1. Ruthenium-106 brachytherapy for iris and iridociliary melanomas.
Marinkovic M; Horeweg N; Laman MS; Bleeker JC; Ketelaars M; Peters FP; Luyten GPM; Creutzberg CL
Br J Ophthalmol; 2018 Aug; 102(8):1154-1159. PubMed ID: 29122824
[TBL] [Abstract][Full Text] [Related]
2. Ruthenium plaque radiation therapy for iris and iridociliary melanomas.
Razzaq L; Keunen JE; Schalij-Delfos NE; Creutzberg CL; Ketelaars M; de Keizer RJ
Acta Ophthalmol; 2012 May; 90(3):291-6. PubMed ID: 20670343
[TBL] [Abstract][Full Text] [Related]
3. Irido-cilio-choroidal melanoma in a 5-year-old boy treated by Ru-106 brachytherapy.
Pe'er J; Averbukh E; Frenkel S
Clin Exp Ophthalmol; 2009 Sep; 37(7):742-3. PubMed ID: 19788674
[No Abstract] [Full Text] [Related]
4. Ruthenium plaque radiation for iris and iridociliary melanomas: development of dry eyes?
Razzaq L; de Keizer RJ
Br J Ophthalmol; 2010 Nov; 94(11):1549-50. PubMed ID: 20516146
[No Abstract] [Full Text] [Related]
5. Ruthenium-106 brachytherapy for choroidal melanoma without transpupillary thermotherapy: Similar efficacy with improved visual outcome.
Marinkovic M; Horeweg N; Fiocco M; Peters FP; Sommers LW; Laman MS; Bleeker JC; Ketelaars M; Luyten GP; Creutzberg CL
Eur J Cancer; 2016 Nov; 68():106-113. PubMed ID: 27741435
[TBL] [Abstract][Full Text] [Related]
6. Plaque radiation therapy for malignant melanoma of the iris and ciliary body.
Finger PT
Am J Ophthalmol; 2001 Sep; 132(3):328-35. PubMed ID: 11530044
[TBL] [Abstract][Full Text] [Related]
7. Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years' experience with beta-rays).
Rouberol F; Roy P; Kodjikian L; Gérard JP; Jean-Louis B; Grange JD
Am J Ophthalmol; 2004 May; 137(5):893-900. PubMed ID: 15126155
[TBL] [Abstract][Full Text] [Related]
8. Use of Ruthenium-106 Brachytherapy for Iris Melanoma: The Scottish Experience.
Agraval U; Sobti M; Russell HC; Lockington D; Ritchie D; Cauchi P; Kemp EG; Chadha V
Br J Ophthalmol; 2018 Jan; 102(1):74-78. PubMed ID: 28600302
[TBL] [Abstract][Full Text] [Related]
9. Ruthenium-106 plaque brachytherapy for uveal melanoma.
Tarmann L; Wackernagel W; Avian A; Mayer C; Schneider M; Winkler P; Langmann G
Br J Ophthalmol; 2015 Dec; 99(12):1644-9. PubMed ID: 25979763
[TBL] [Abstract][Full Text] [Related]
10. Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population.
Bergman L; Nilsson B; Lundell G; Lundell M; Seregard S
Ophthalmology; 2005 May; 112(5):834-40. PubMed ID: 15878063
[TBL] [Abstract][Full Text] [Related]
11. Metastatic disease, eye retention and visual function in conservative treatment of uveal melanoma.
Bornfeld N; Chauvel P; Sauerwein W; Friedrichs W; Tiburtius T; Wessing A; Foerster MH
Front Radiat Ther Oncol; 1997; 30():97-110. PubMed ID: 9205890
[No Abstract] [Full Text] [Related]
12. [Plaque radiotherapy for anterior uveal melanomas].
Saakyan SV; Amiryan AG; Valskiy VV; Mironova IS
Vestn Oftalmol; 2015; 131(2):5-12. PubMed ID: 26080576
[TBL] [Abstract][Full Text] [Related]
13. Ultrasound biomicroscopy features of iris and ciliary body melanomas before and after brachytherapy.
Torres VL; Allemann N; Erwenne CM
Ophthalmic Surg Lasers Imaging; 2005; 36(2):129-38. PubMed ID: 15792314
[TBL] [Abstract][Full Text] [Related]
14. Ciliary body melanoma with limited nodular extrascleral extension and diffuse iris-angle infiltration treated by whole anterior segment plaque radiotherapy.
Gray ME; Corrêa ZM; Augsburger JJ; Barrett W
Int Ophthalmol; 2007 Aug; 27(4):273-6. PubMed ID: 17468833
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of Ru-106/Rh-106 brachytherapy for posterior uveal melanoma.
Lommatzsch PK; Werschnik C; Schuster E
Graefes Arch Clin Exp Ophthalmol; 2000 Feb; 238(2):129-37. PubMed ID: 10766281
[TBL] [Abstract][Full Text] [Related]
16. Plaque radiotherapy treatment with ruthenium-106 for iris malignant melanoma.
Tsimpida M; Hungerford J; Arora A; Cohen V
Eye (Lond); 2011 Dec; 25(12):1607-11. PubMed ID: 21941358
[TBL] [Abstract][Full Text] [Related]
17. Management of ciliary body melanoma with iodine-125 plaque brachytherapy.
Krema H; Simpson ER; Pavlin CJ; Payne D; Vasquez LM; McGowan H
Can J Ophthalmol; 2009 Aug; 44(4):395-400. PubMed ID: 19606159
[TBL] [Abstract][Full Text] [Related]
18. [High-dose 106Ruthenium plaque brachytherapy for posterior uveal melanoma. A clinico-pathologic study].
Heindl LM; Lotter M; Strnad V; Sauer R; Naumann GO; Knorr HL
Ophthalmologe; 2007 Feb; 104(2):149-57. PubMed ID: 17123048
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant proton beam irradiation vs. adjuvant ruthenium brachytherapy in transscleral resection of uveal melanoma.
Böker A; Pilger D; Cordini D; Seibel I; Riechardt AI; Joussen AM; Bechrakis NE
Graefes Arch Clin Exp Ophthalmol; 2018 Sep; 256(9):1767-1775. PubMed ID: 29907945
[TBL] [Abstract][Full Text] [Related]
20. Plaque radiotherapy for management of ciliary body and choroidal melanoma with extraocular extension.
Gündüz K; Shields CL; Shields JA; Cater J; Brady L
Am J Ophthalmol; 2000 Jul; 130(1):97-102. PubMed ID: 11004266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
